-

07:01:39 PM

EDSA Stock News

EDSA - Edesa Biotech Inc

03/16/23 4:10 PM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD)

RHEA-AI

neutral

03/15/23 8:10 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage

RHEA-AI

neutral

02/10/23 9:00 AM

Nasdaq : EDSA

earningslow float

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business.

RHEA-AI

very positive

02/01/23 8:15 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases,

RHEA-AI

neutral

01/17/23 8:30 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage

RHEA-AI

neutral

12/20/22 8:30 AM

Nasdaq : EDSA

low float

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and

RHEA-AI

very positive

12/16/22 9:00 AM

Nasdaq : EDSA

earningslow float

Edesa Biotech Reports Fiscal Year 2022 Results

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business.

RHEA-AI

positive

12/02/22 8:00 AM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will participate in a panel discussion and host one-on-one

RHEA-AI

neutral

11/03/22 9:00 AM

Nasdaq : EDSA

low float

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private placement directly with investors priced at-the-market

RHEA-AI

neutral

09/30/22 8:00 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa Biotech, Inc.

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

EDSA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.edesabiotech.com
Security nameEdesa Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees16
Tags
- Biotechnology
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Edesa Biotech Inc

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that it's developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.